Liver Cirrhosis: Causes, Complications and Treatment

Liver cirrhosis is the irreversible end stage of chronic liver injury, in which progressive fibrosis (scarring) replaces functional liver tissue. As fibrous scar tissue accumulates, normal liver architecture — including the vascular channels and hepatocytes that perform the liver's hundreds of metabolic functions — is distorted and destroyed. The result is progressive liver failure and portal hypertension (elevated pressure in the portal venous system), which drive the life-threatening complications of advanced cirrhosis.

Cirrhosis affects an estimated 100–120 million people worldwide and causes approximately 1.3 million deaths annually. In China, cirrhosis is particularly prevalent due to the extremely high burden of chronic hepatitis B virus (HBV) infection — China accounts for approximately one-third of all chronic HBV carriers globally.

How Cirrhosis Develops

Chronic liver injury from any cause — if sustained over years — triggers the same fibrotic repair response:

1. Repeated hepatocyte death (from virus, alcohol, fat, or immune attack) triggers inflammation
2. Activated hepatic stellate cells (the liver's "scar cells") proliferate and deposit collagen fibres
3. Fibrous tissue accumulates in the liver parenchyma (perisinusoidal fibrosis) and portal tracts
4. Normal hepatic lobular architecture is replaced by fibrous septa encircling regenerative nodules
5. The vascular architecture is distorted — blood flow through the hepatic sinusoids is obstructed, and portal venous pressure rises (portal hypertension)

Fibrosis progresses from mild (Metavir F1) through significant (F2), advanced (F3 — "pre-cirrhosis"), to established cirrhosis (F4). Early fibrosis can partially regress if the causative agent is removed (e.g., viral cure, alcohol cessation); established cirrhosis is largely irreversible but can stabilise.

Causes

Chronic Hepatitis B (HBV) — Leading Cause in China and Asia

Chronic infection with HBV causes ongoing hepatocyte destruction by immune-mediated attack. HBV cirrhosis develops in approximately 20–40% of chronically infected individuals over 20–40 years. The risk is higher with high viral loads, HBeAg-positive status, alcohol co-use, co-infection with HDV, and male sex.

China has approximately 70–90 million chronic HBV carriers (HBsAg-positive). Long-term antiviral therapy (tenofovir, entecavir) suppresses viral replication, halts or reverses fibrosis progression, and dramatically reduces the risk of hepatocellular carcinoma (HCC) — the most feared complication of HBV cirrhosis.

Chronic Hepatitis C (HCV)

HCV causes insidious liver inflammation over decades — 80% of acute HCV infections become chronic. Approximately 20–30% of chronically infected patients develop cirrhosis within 20–30 years. HCV is now curable with direct-acting antiviral (DAA) agents (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) — 8–12-week oral courses achieve sustained virological response (SVR, effectively cure) in >95% of patients. Achieving SVR stops fibrosis progression and reduces — though does not eliminate — HCC risk.

Alcohol-Related Liver Disease (ARLD)

Chronic excessive alcohol consumption (>14 units/week for women; >21 units/week for men) causes alcoholic fatty liver (steatosis) → alcoholic hepatitis → cirrhosis. The dose-response relationship is linear. Alcohol is the most prevalent cause of cirrhosis in Western countries. Complete abstinence can halt and partially reverse fibrosis; continued drinking in established cirrhosis dramatically worsens prognosis.

Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD)

The hepatic manifestation of metabolic syndrome — fat accumulates in hepatocytes (steatosis) in patients with obesity, type 2 diabetes, dyslipidaemia, and hypertension. In approximately 20–25% of those with NAFLD, inflammatory changes (non-alcoholic steatohepatitis — NASH) develop, which can progress to cirrhosis over 15–20 years. NAFLD is now the most rapidly growing cause of cirrhosis and HCC in developed countries.

Other Causes

• Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) — autoimmune bile duct destruction
• Autoimmune hepatitis (AIH) — autoimmune attack on hepatocytes; responds to immunosuppression
• Hereditary haemochromatosis — iron overload; treated by venesection
• Wilson's disease — copper accumulation; treated with chelation
• Alpha-1 antitrypsin deficiency
• Budd-Chiari syndrome — hepatic vein thrombosis

Stages of Cirrhosis

Cirrhosis is broadly divided into compensated and decompensated:

Compensated cirrhosis — the liver, despite significant fibrosis, maintains adequate function. Patients may be asymptomatic or have only non-specific fatigue, mild right upper quadrant discomfort, and spider naevi on examination. Median survival >12 years. The goal of treatment is to prevent progression to decompensation.

Decompensated cirrhosis — failure of hepatic compensation, defined by the development of one or more of:

• Variceal haemorrhage
• Ascites
• Spontaneous bacterial peritonitis (SBP)
• Hepatic encephalopathy (HE)
• Hepatorenal syndrome (HRS)

Median survival after first decompensation: 1–2 years without liver transplantation.

Complications of Portal Hypertension

Portal hypertension — elevated pressure in the portal vein (normal <5 mmHg; clinically significant portal hypertension: >10 mmHg; high risk of variceal haemorrhage: >12 mmHg) — drives most major complications:

Oesophageal and Gastric Varices

Collateral venous channels develop between the portal and systemic venous systems to decompress the portal pressure. The most dangerous site is the oesophagus and gastric cardia — submucosal varices here may rupture, causing massive, potentially fatal upper GI haemorrhage.

Variceal haemorrhage:

• Presents with haematemesis (vomiting blood) and/or melaena (black tarry stool)
• 6-week mortality approximately 15–20% with modern management; historically 30–50%
• Emergency treatment: IV terlipressin or somatostatin analogue (octreotide); urgent upper GI endoscopy for variceal band ligation (EVL); IV antibiotics (prevent SBP); possibly TIPS (transjugular intrahepatic portosystemic shunt) for refractory bleeding
• Primary prophylaxis: non-selective beta-blocker (propranolol or carvedilol) for large varices before first bleed; or EVL
• Secondary prophylaxis: EVL + beta-blocker after each bleeding episode; TIPS if refractory

Ascites

Accumulation of fluid in the peritoneal cavity — the most common decompensating event (develops in 50% of patients with compensated cirrhosis within 10 years). Caused by sodium and water retention (aldosterone activation), splanchnic vasodilation, and hypoalbuminaemia (low albumin = reduced oncotic pressure).

Treatment:

• Sodium restriction (<88 mmol/day) and aldosterone antagonist diuretics (spironolactone ± furosemide)
• Large-volume paracentesis (LVP) for tense or refractory ascites — draining 4–6 litres per session with IV albumin to prevent post-paracentesis circulatory dysfunction
• TIPS for refractory ascites unresponsive to diuretics

Spontaneous Bacterial Peritonitis (SBP)

Bacterial infection of ascitic fluid without an obvious surgical cause — translocation of gut bacteria across the impaired gut barrier. Presents with fever, abdominal pain, and deteriorating liver function. Diagnosed by ascitic fluid neutrophil count ≥250/mm³. Treated with IV cefotaxime or ceftriaxone; prophylactic antibiotics (norfloxacin) reduce recurrence. SBP carries approximately 30% in-hospital mortality.

Hepatic Encephalopathy (HE)

Brain dysfunction caused by the liver's failure to detoxify ammonia and other metabolites produced in the gut. The spectrum ranges from subtle cognitive changes (covert HE — detected only on neuropsychological testing) to frank confusion, disorientation, personality change, flapping tremor (asterixis), and coma.

Grades (West Haven Criteria):

• Grade 1: Mild confusion, altered sleep
• Grade 2: Moderate confusion, disorientation
• Grade 3: Severe confusion, somnolence
• Grade 4: Coma

Treatment: lactulose (reduces ammonia absorption); rifaximin (antibiotic reducing ammonia-producing gut bacteria); identify and treat precipitants (infection, GI bleeding, dehydration, constipation, sedatives); TIPS is contraindicated in HE.

Hepatorenal Syndrome (HRS)

Acute kidney injury in advanced cirrhosis — a functional (not structural) kidney failure caused by extreme splanchnic vasodilation reducing effective renal perfusion. Type 1 HRS: rapid onset, severe (creatinine doubling to >226 µmol/L within 2 weeks); type 2 HRS: progressive, moderate. Treatment: terlipressin + IV albumin. Prognosis is poor without liver transplantation.

Diagnosis and Monitoring

Laboratory Tests

• Liver function tests: elevated bilirubin, low albumin, prolonged INR (prothrombin time) in advanced disease
• Liver blood panel: ALT, AST (often paradoxically normal or low in burned-out cirrhosis), ALP, GGT
• FBC: thrombocytopenia (splenomegaly trapping platelets) is a reliable early sign of portal hypertension
• Aetiology screen: HBsAg, HBV DNA, anti-HCV, HCV RNA, ANA, AMA, ferritin, copper, caeruloplasmin

Non-Invasive Fibrosis Assessment

• Fibroscan (transient elastography): measures liver stiffness in kilopascals — highly correlated with fibrosis stage; kPa >12–15 indicates significant fibrosis/cirrhosis; replaces liver biopsy in many settings
• Blood-based scores: APRI, FIB-4, ELF score — validated fibrosis indices from routine blood tests

Liver Biopsy

The historical gold standard — percutaneous needle biopsy provides histological staging. Now reserved for cases where non-invasive tests are inconclusive or where histology changes management (e.g., autoimmune hepatitis grading).

Upper GI Endoscopy

Screening for oesophageal varices in all newly diagnosed cirrhosis patients, then repeated every 2–3 years (or annually in decompensated cirrhosis).

HCC Surveillance

All cirrhotic patients require 6-monthly liver ultrasound ± AFP measurement to detect hepatocellular carcinoma at an early, treatable stage. In high-risk patients (HBV cirrhosis, active HCV), MRI-based surveillance is preferred.

Treatment

Treating the Underlying Cause

• HBV: tenofovir alafenamide (TAF) or entecavir — long-term or lifelong antiviral therapy; dramatically reduces fibrosis progression and HCC risk
• HCV: 8–12-week direct-acting antiviral (DAA) cure — sofosbuvir/velpatasvir or glecaprevir/pibrentasvir; SVR achieves functional cure
• Alcohol: complete abstinence — the most important intervention in ARLD; even in established cirrhosis, abstinence substantially improves prognosis
• NAFLD: weight loss (5–10% body weight), metabolic risk factor control; new approved treatment: resmetirom (Rezdiffra) for non-cirrhotic NASH with significant fibrosis
• Autoimmune hepatitis: prednisolone + azathioprine

Liver Transplantation

Liver transplantation is the only definitive treatment for end-stage cirrhosis. It restores normal liver function and cures portal hypertension.

Indications: MELD score ≥15 (Model for End-stage Liver Disease — a score based on bilirubin, INR, and creatinine predicting 3-month mortality); recurrent or refractory decompensation (variceal bleeding, ascites, HE); HCC within Milan criteria (single tumour ≤5 cm or ≤3 tumours all ≤3 cm).

Deceased donor transplantation: waiting list allocation based on MELD score.

Living donor liver transplantation (LDLT): a healthy donor (typically a family member) donates their right lobe (60% of total liver volume); the donor's liver regenerates within 6–8 weeks. LDLT is particularly developed in Asia, where deceased donor availability is limited by cultural attitudes to organ donation. China's LDLT programme is among the largest in the world.

Liver and GI Care in China

China's hepatology and liver transplantation centres offer:

• Comprehensive hepatitis assessment: HBV/HCV viral load, HBsAg quantification, genotyping, Fibroscan elastography, liver MRI, and haematology
• HCV cure: all DAA regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) available, including Chinese domestic generics; 8–12 weeks to cure
• HBV long-term treatment: TAF and entecavir available; comprehensive monitoring programme
• TIPS procedure: experienced interventional radiology teams for transjugular intrahepatic portosystemic shunting
• High-volume LDLT programme: among the world's most experienced LDLT centres; comprehensive donor and recipient evaluation
• Cost: care in China is generally less expensive than UK private treatment, but the hospital prices each case individually — ask us for the written quote before you commit.
• Full English care navigation from assessment through treatment and long-term surveillance

Contact a ChinaMedicalTour care navigator to arrange a liver disease assessment, hepatitis treatment, or transplantation consultation.

---

Medical content based on MSD Manuals and international hepatology guidelines (EASL, AASLD). Evidence reviewed 2025.

Frequently Asked Questions

Can overseas patients submit endoscopic or imaging reports for digestive condition review?

Yes. Endoscopy reports, abdominal ultrasound, CT, or MRI scans can be reviewed by Chinese gastroenterologists to evaluate diagnostic workups and therapeutic strategies before traveling.

What digestive diagnostic and therapeutic procedures are available in Chinese hospitals?

Tertiary digestive endoscopy centers offer high-definition chromoendoscopy, endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), capsule endoscopy, and multidisciplinary IBD management.

How are digestive consultations and procedures arranged for international visitors?

Outpatient specialist consultations, bowel preparation coordination, and day surgery or inpatient bookings are confirmed directly with participating tertiary hospital departments.